^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ET-190

    i
    Other names: ET-190, ET190L1-ARTEMIS T cell therapy, ET190L1, ET190L1-AbTCR T-cells, ET190L1-ARTEMIS T cells
    Associations

    News

    Trials
    Company:
    Eureka Therap
    Drug class:
    CD19 inhibitor, γδ TCR modulator
    Related drugs:
    Associations

    News

    Trials
    3years
    Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma (clinicaltrials.gov)
    P1, N=4, Completed, Eureka Therapeutics Inc. | Active, not recruiting --> Completed | N=21 --> 4 | Trial completion date: Jun 2021 --> Dec 2020 | Trial primary completion date: Jun 2021 --> Dec 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    ET-190